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Sex-specific-differences in cardiometabolic risk in
type 1 diabetes: a cross-sectional study
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Johannes Saukel3, Julienne Johnson4 and Rosa Lemmens-Gruber2
Abstract
Background: Little is known about the impact of sex-specific differences in the management of type 1 diabetes
(T1DM).
Thus, we evaluated the influence of gender on risk factors, complications, clinical care and adherence in patients
with T1DM.
Methods: In a cross-sectional study, sex-specific disparities in glycaemic control, cardiovascular risk factors, diabetic
complications, concomitant medication use and adherence to treatment recommendations were evaluated in 225
consecutive patients (45.3% women) who were comparable with respect to age, diabetes duration, and body mass
index.
Results: Although women with T1DM had a higher total cholesterol than men, triglycerides were higher in obese
men and males with HbA1c>7% than in their female counterparts. No sex differences were observed in glycaemic
control and in micro- or macrovascular complications. However, the subgroup analysis showed that nephropathy
was more common in obese men, hyperlipidaemic women and all hypertensive patients, whereas peripheral
neuropathy was more common in hyperlipidaemic women. Retinopathy was found more frequently in women
with HbA1c>7%, obese men and in both sexes with a long duration of diabetes. The multivariate analysis revealed
that microvascular complications were associated with the duration of disease and BMI in both sexes and with
hyperlipidaemia in males. The overall adherence to interventions according to the guidelines was higher in men
than in women. This adherence was concerned particularly with co-medication in patients diagnosed with
hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the
prescription of statins.
Conclusions: Our data showed sex differences in lipids and overweight in patients with T1DM. Although glycaemic
control and the frequency of diabetic complications were comparable between the sexes, the overall adherence to
guidelines, particularly with respect to the prescription of statins and aspirin, was lower in women than in men.
Keywords: Type 1 diabetes mellitus, Gender, Diabetic complications, Cardiovascular risk, Blood pressure, Lipid profile
Background
Type 1 diabetes (T1DM) is a chronic disease that is still
a challenge for both patients and their physicians. Patient
education and self-empowerment, good metabolic control
and cardiovascular risk management are important to pro-
tect from the early development of diabetic complications
and increased mortality. Recently, a doubling of new cases
of T1DM in European children younger than 5 years and
a rise by 70% in the prevalent cases younger than 15 years
between 2005 and 2020 was predicted [1]. Therefore,
better knowledge about risk factors and the needs of these
patients as well as adequate health-care resources to meet
these needs are necessary.
Contrary to type 2 diabetes, which is usually characterised
by overweight/obesity and increasing age, the literature on
the potential sex and gender differences in type 1 diabetes
concerning cardiovascular risk factors, metabolic control
and drug therapy is scarce [2-4]. Data from the EURODIAB
* Correspondence: alexandra.kautzky-willer@meduniwien.ac.at
1Gender Medicine Unit, Department of Internal Medicine III, Division of
Endocrinology and Metabolism, Medical University of Vienna, Waehringer
Guertel 18-20, 1090, Vienna, Austria
Full list of author information is available at the end of the article
CARDIO
VASCULAR 
DIABETOLOGY
© 2013 Kautzky-Willer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Kautzky-Willer et al. Cardiovascular Diabetology 2013, 12:78
http://www.cardiab.com/content/12/1/78
PCS recently showed that women with type 1 diabetes
had higher total cholesterol concentrations and that
higher triglyceride but lower HDL cholesterol levels
were predictors of coronary heart disease in women [5]. In
contrast, sialic acid and fibrinogen were strong predictors
of CHD only in men with type 1 diabetes beyond the effect
of the established risk factors [6]. Data from a German
database [7] revealed that female gender, age, duration of
diabetes and minority status were significantly associated
with poor glycaemic control. However, most studies in
T1DM have investigated children or patients at a young age.
Therefore, we aimed to investigate in a cross-sectional
study whether gender differences are relevant between
male and female adult patients with T1DM with regard to
metabolic control, cardiovascular risk factors, the presence
of the metabolic syndrome, micro- and macrovascular
diabetic complications, drug therapy and adherence to
clinical recommendations.
Methods
Study design and patients
This study was a cross sectional survey of patient data
from medical records and patient questionnaires and
interviews to determine the adherence to a medication
assessment tool. This study was approved by the Ethics
Committee of the Medical University of Vienna and
conducted in accordance with the Helsinki Declaration.
In total, 225 patients (45.3% women and 54.7% men)
with T1DM, attending the diabetes outpatient clinic at the
Medical University of Vienna between March 2009 and
August 2009, fulfilled the inclusion criteria (age ≤75 years,
T1DM, a documented history of the presence or absence of
coronary heart disease, obese and non-obese diabetics
aged ≥18 years, and having given informed consent). The
required sample size was calculated using standard for-
mulae for sampling for a survey to produce percentage
frequency rates of nominal data within conventionally
acceptable error rates (margin of error 5%) and 95% CIs.
Sampling was performed using standard data collection. A
previously described questionnaire was used to obtain
information about age, known duration of T1DM, height,
weight, adherence to drug treatment, smoking habits,
alcohol consumption, parental history of diabetes, blood
pressure, glycaemic control, lipid profile, and parameters of
liver and kidney function [8,9]. In addition, the presence of
diabetic microvascular and macrovascular complications
and a history of previous percutaneous transluminal coron-
ary angioplasty (PTCA) or coronary artery bypass surgery
(CABG) were assessed. The information about life-style pa-
rameters, familial predisposition for cardiovascular disease
(CVD) and parental history of diabetes was self-reported,
but all data concerning weight, height, duration of diabetes,
medical history and clinical characteristics were immedi-
ately confirmed and completed using the clinical records.
All patients maintained a stable weight, and moderate
physical activity and nutrition therapy were recommended
for all.
Subgroup analyses
To identify criteria for which adherence was statistically
significant among the subgroups, we classified patients
according to age, duration of disease, body weight,
glycaemic control, co-morbidities and gender (Figure 1).
The subgroup analyses were performed to compare the
above-mentioned criteria. Patients with CVD, defined as is-
chaemic heart disease, myocardial infarction, and/or angina
pectoris, stroke and transient ischaemic attacks were
considered to require secondary prevention.
Metabolic syndrome (MetS) was defined according to the
European Guidelines on cardiovascular disease prevention
[10] and the World Health Organization criteria [11] by
the presence of diabetes mellitus (DM)/insulin resistance
plus ≥2 of the following parameters: obesity (body mass
index [BMI] ≥30 kg/m2), hypertension (blood pressure
[BP] ≥140/90 mmHg or the use of antihypertensive drugs),
and dyslipidaemia (triglycerides [TG] ≥1.71 mmol/L
and/or HDL-C <0.9 mmol/L for men and <1.03 mmol/L
for women). Insufficient glycaemic control was defined as
HbA1c >7%, and poor glycaemic control as HbA1c >8%.
Adherence to guidelines and medication assessment tool
To test the adherence of the patient populations to
evidence-based clinical prescribing recommendations, a
medication assessment tool (MAT) was employed [8,12].
This instrument is based on the guidelines established
by the Scottish Intercollegiate Guidelines Network [13],
which is in accordance with the guidelines of the American
Diabetes Association and the European Society of
Cardiology [14,15]. Furthermore, a review of NICE
guidelines 43 [16], 34 [17], and 48 [18] and of SIGN
guideline 97 [19] was performed. The final medication
assessment tool comprised 30 criteria including 13 criteria
for general cardio-preventive measures, 10 for hypertension,
3 for diabetes management, and 4 for anti-obesity medica-
tion. For each patient, each criterion item was judged as
“applicable”, “insufficient data” (lack of information), “not
applicable” (criterion relevant for patient but the patient’s
data did not meet the qualifying statement) or “justified
non-adherence” (explanation for the patient’s treatment not
meeting a quality criterion). Adherence to the guideline
recommendations was calculated as previously described
in detail [8,12]. Adherence above 70% was arbitrarily
judged as a high level of adherence, between 50 and
69% as intermediate and below 50% as low.
Statistics
The levels of adherence were compared using the χ2 test
and P<0.05 as the threshold for statistical significance. A
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Microsoft Access (Microsoft Corporation, Redmond, WA)
database was created, from which the data from the specific
subgroups were extracted. These data were statistically
evaluated using SPSS 16.0 (SPSS Inc., Chicago, IL).
For metric and ordinal characteristics, the number of
patients and arithmetic means with standard errors are
given. For the evaluation of statistically significant
sex-dependent differences within the whole sample
and specific subgroups, Student’s t test, Welch t test and
Mann–Whitney U test were used, depending on the
sample size and test criteria. For nominal characteristics,
the number of patients and percentages are given. Statisti-
cally significant sex-dependent differences for the whole
sample and specific subgroups were calculated using the χ2
test and the Fisher exact test. Statistical significance was
determined at levels of P<0.05, P<0.01, and P<0.001.
The multivariate discriminant function analysis tool
(©Statistica 10.0, StatSoft, Germany) was used to determine
which variables discriminate between healthy and sick
persons for the three important complications: nephropathy,
peripheral neuropathy, and retinopathy. We used the
so-called forward stepwise analysis. In this type of analysis,
a model of discrimination is built step-by-step. Specifically,
at each step, all variables are reviewed and evaluated to
determine which one will contribute most to the dis-
crimination between groups. The stepwise procedure is
“guided” by the respective F to enter and F to remove
values. The F value for a variable indicates its statistical
significance in the discrimination between groups, that
is, it is a measure of the extent to which a variable
makes a unique contribution to the prediction of group
membership. The generated classification matrices provide
evidence of correctly assigned patients.
The general regression model tool (©Statistica 10.0) was
used to analyse the multivariate regression of 11 continuous
variables (duration of T1DM, systolic and diastolic blood
pressure, blood glucose, HbA1c, BMI, total cholesterol,
LDL, HDL, total cholesterol/HDL ratio, and triglycerides)
against the ordinal arranged combination of the three
binary variables - nephropathy (1), peripheral neuropathy
(2), and retinopathy (3) according to the formula (1 + 2) +
(1 + 3) + (2 + 3). The model was built up with the tool
combination multiple regression (method best subsets) +
ordinal multinomial distribution + the logit link function.
One major output is an ordered list of the so-called Wald
statistic of the used variables with the amount of the
power and probability of the prediction of the ordinal
multinomial variable.
Results
Metabolic syndrome and patient profile
MetS affected 13.5% of the entire study sample (Table 1).
Sex-dependent differences were observed regarding hyper-
lipidaemia, with more women having hyperlipidaemia with
a significantly higher total cholesterol and HDL-cholesterol
concentration compared with men (Table 1). This finding
of significantly higher total cholesterol levels in women was
observed in all subgroups (see Figure 1) except in the
overweight patients and patients ≥60 years. Especially in the
subgroups of obese and hypertonic women, not only was
total cholesterol significantly higher than in their respective
male subgroups (220.8 [54.1] vs. 183.7 [41.2] mg/dl, P<0.05,
and 206.2 [42.6] vs. 185.9 [34.6] mg/dl, P<0.05, respectively)
but LDL cholesterol was also significantly higher (135.0
[48.5] vs. 98.0 [34.8], P<0.05, and 114.5 [39.2] vs. 100.1
[27.8] mg/dl, P<0.05). Remarkably, compared with the
whole female sample and other female subgroups,
HDL cholesterol in obese women was lowest at 62.8
[23.0] mg/dl. Consequently, this lower HDL cholesterol
value resulted in an increase in the total cholesterol/HDL
ratio, which was higher in men than in women in the total
sample (Table 1) and in all other subgroups. In obese
patients, however, the total cholesterol/HDL ratio of
3.65 [1.15] for women was not different from that of
Figure 1 Description of the subgroups.
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men (3.64 [0.91]). Furthermore, in all male subgroups,
triglycerides were elevated and higher than those in
their female counterparts, particularly in obese men
(172.3 [75.2] vs. 115.08 [71.2], P<0.05) and in male
patients with insufficient glycaemic control (132.9 [68.7]
vs. 109.7 [63.3], P<0.05).
Diabetic complications
In the entire sample, no significant sex-dependent dif-
ferences for the incidence of micro- and macrovascular
complications were observed (Table 2). Macrovascular
diseases occurred rarely in our sample of T1DM patients,
whereas microvascular complications were observed more
frequently (Table 2). They already occurred at an earlier
stage of T1DM. Nephropathy, peripheral neuropathy and
retinopathy were found in all T1DM patients in both the
presence and absence of other risk factors. The univariate
analysis highlights an increased risk for the development
of nephropathy in obese men, hyperlipidaemic women
and hypertensive men and women (Figure 2A, Table 3). A
significantly increased risk for peripheral neuropathy was
only observed in hyperlipidaemic women (Figure 2B,
Table 3). The threat for retinopathy was significantly higher
in men and women suffering from T1DM more than
10 years, in women with insufficient glycaemic control, and
in hypertensive patients (Figure 2C, Table 3). Obese men
had a significantly higher risk to develop retinopathy than
normal weight males. However, there were no significant
differences between obese and overweight patients or
between normal weight and overweight patients.
Hence, a multivariate discriminant function analysis was
conducted to determine which parameters discriminate
between diabetic patients without microvascular diseases
and those suffering from neuropathy, peripheral neur-
opathy or retinopathy. Our data confirmed the pivotal role
of the duration of diabetes for the onset and progression of
retinopathy and neuropathy (Table 3). In addition, in our
sample, diabetic retinopathy was significantly associated
with dyslipidaemia (males and females) and body weight
(males) (Table 3). The multivariate regression analysis of
eleven parameters against the three variables of nephropa-
thy, peripheral neuropathy and retinopathy revealed that
the duration of disease and body weight in male and female
patients and dyslipidaemia in males were joint risk factors
for the development of microvascular diseases.
Pharmacotherapy
The adherence to interventions according to the respective
guidelines is listed in Tables 4, 5 and 6, ranked from highest
to lowest adherence. Interestingly, the overall adherence
was higher in men (56.9 [47.1-62.7]) than in women
(46.5 [37.1-55.9]) (P = 0.0573).
Low levels of adherence were found with respect to
advice for smoking cessation in patients who contin-
ued smoking (Table 4), in the prescription of aspirin
(Tables 4 and 5), and in the achievement of target LDL
cholesterol, triglyceride (Table 4), and blood pressure
levels (Table 5) and HbA1c<6.5% (Table 6). Both genders
indicated low adherence to the criterion “Patient who is
Table 2 Percentage of men (n=123) and women (n=102)
with diabetic complications
Micro- and macrovascular diseases Women Men P-value
Familial predisposition for CVD (%) 25.3 16.2 0.112
Nephropathy (%) 13.7 15.2 0.755
Peripheral neuropathy (%) 14.7 11.4 0.487
Retinopathy (%) 32.6 29.5 0.635
Peripheral artery occlusive disease (PAOD) (%) 3.2 2.9 1.000
PTCA/CABG (%) 4.2 1.0 0.193
Angina pectoris (%) 0 1.9 0.499
Cerebral ischemia (%) 2.1 1.0 0.475
Myocardial infarction (%) 1.1 0 0.605
Cardiovascular disease (CVD), Percutaneous Coronary Transluminal
Angioplasty/Coronary artery bypass grafting (PCTA/CABG).
Table 1 Demographic data and clinical characteristics of
T1DM patients
Characteristics Women Men
(n=102) (n=123)
Age (years) 41.3±13.6 43.1±13.9
Percentage of geriatric patients (>60 years) 8.8 13.8
Age (years) at diagnosis 19.2±10.2 21.4±11.5
Duration (years) of disease 19.3±7.7 17.3±10.4
Smokers (%) 29.1 36.3
Alcohol abstinence (%) 53.5§§§ 20.4
Metabolic syndrome (%) 12.6 14.3
Blood glucose (mg/dl) 122.9±50.4 123.8±56.4
HbA1c (%) 7.6±1.0 7.5±1.1
HbA1c<6.5% (%) 26.5 29.3
Hypertension (%) 44.2 46.7
Systolic blood pressure (mmHg) 135.5±18.9 136.9±17.4
Diastolic blood pressure (mmHg) 82.7±12.3 82.9±8.7
BMI (kg/m2) 25.5±4.9 26.3±3.4
Overweight (%) 33.3 44.7§§§
Obese (%) 12.7 13.0
Hyperlipidaemia (%) 46.3 35.2
Total cholesterol (mg/dl) 203.1±38.3 186.7±33.6**
HDL cholesterol (mg/dl) 70.6±19.9 59.1±15.9***
LDL cholesterol (mg/dl) 111.1±32.2 103.4±28.2
Total cholesterol/HDL ratio 3.3±1.6 3.6±1.4
Triglycerides (mg/dl) 106.6±69.1 124.6±71.8
Data are shown as mean±SE.
§§§ P < 0.001 by χ2 test, ** P < 0.01 by t test, *** P < 0.001 by t test.
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prescribed a statin has achieved target cholesterol and
triglyceride levels”, but females showed even significantly
(P < 0.01) lower levels than males (Table 4). Furthermore,
female patients older than 50 years were prescribed aspirin
significantly less frequently (P < 0.05) than their male
counterparts. Similarly, in male patients aged <50 years
with prominent risk factors, such as a family history of
CVD, smoking and MetS, only a very low adherence
(5.9% [0–17.1]) for the prescription of aspirin was esti-
mated. However, for female patients, the adherence to
this criterion was zero in our sample. In addition, the
achievement of a target HbA1c<6.5% was significantly
different between men (intermediate adherence) and
women (with low adherence) (P<0.05) (Table 6), whereas
no significant sex-dependent difference in the patients with
insufficient glycaemic control was observed.
High levels of adherence were observed for all other
cardio-preventive and hypertension criteria and for diabetes
management. Although both genders indicated high adher-
ence (92.9% [79.4-100]) to the criterion “Patient diagnosed
with hypertension has a treatment plan that does not
include oral contraceptives, corticosteroids, non-steroidal
anti-inflammatory drugs (NSAIDs), high sodium containing
products, sympathomimetics and/or monoamine oxidase
inhibitors”, the female population showed significantly
(P<0.05) lower levels (84.6%) than their male counterparts
(96.9%) (Table 5). Among the women who had no appro-
priate treatment plan according to the above mentioned
criterion, 4.8% had been prescribed postmenopausal
hormone replacement therapy, which was equalised to oral
contraceptives. In addition, 12.8% of women had been pre-
scribed a corticosteroid, and 1.5% an NSAID. In most cases,
a combination of antihypertensive drugs was administered,
including diuretics, ACE inhibitors, angiotensin II type 1
receptor blockers, calcium antagonists, α1-blockers, and
α2-agonists. In contrast, the prescription of beta-blockers
in post-myocardial infarction patients or patients with
coronary heart disease was significantly lower in men than
in women (68.8% [56.7-80.9] vs. 88.0% [76.1-97.9], P<0.05).
For all other applied criteria concerning cardio-preventive
measurements and the management of hypertension and
T1DM, no significant differences between men and women
were observed (Tables 4, 5 and 6).
Discussion
The T1DM incidence is comparable between men and
women in most populations [20,21] and is linked to
long-term mortality [22,23], particularly in females
with T1DM diagnosed before the age of 30 years [24].
Childhood-onset T1DM with at least 25 years of follow-up
showed no sex-differences in the survival and mortality
trends [25]; however, these female patients were 13 times
more likely to die than age-matched women in the general
population, whereas these male patients only had a 5-fold
Figure 2 Percentage of diabetic complications in the presence
and absence of particular risk factors. The percentage of women
and men with nephropathy (A), peripheral neuropathy (B) and
retinopathy (C) is shown for several patient subgroups. The significance
of the differences between patient subgroups in the presence and
absence of particular risk factors was calculated and is indicated by
asterisks (* P<0.05, ** P<0.01, *** P<0.001). 2A: The risk for the
development of nephropathy increased significantly in obese men,
hyperlipidaemic women and hypertensive male and female patients
compared with normal weight men, normolipidaemic women and
normotensive male and female patients. 2B: There was a significantly
more frequent occurrence of peripheral neuropathy in hyperlipidaemic
women than in normolipidaemic women. 2C: Retinopathy was
observed significantly more often in male and female patients with a
longer duration of disease, in women with poor glycaemic control, in
obese men, and in hypertensive men and women compared with
patients in the respective subgroups without these risk factors.
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increased mortality rate compared with the male back-
ground population. Similar data stratified by sex were also
reported from Norway [22] and the Diabetes UK Cohort
Study [26]. Thus, although young women are usually
protected from cardiovascular disease and nephropa-
thy compared with males, women with T1DM appear to be
a very vulnerable group of patients. The female sex was
speculated to completely lose its general survival advantage
in diabetic subjects, and increasing effects on the long-term
complications and potential differences in treatment may
contribute to this finding [25].
Therefore, in this analysis, we studied sex differences
regarding metabolic control, complications and pharma-
cological treatment with regard to the adherence to
guidelines in a characteristic sample of T1DM patients
treated at the outpatient department of a university
clinic. The sample consisted of a homogeneous group of
Central European patients. They were middle-aged with
a quite long duration of disease and onset after puberty
in most cases. Most were normal-weight or moderately
overweight, and less than 15% of men and women fulfilled
the criteria of metabolic syndrome, which is lower than
the rate usually found in subjects of comparable age in
Europe [27]. However, the rate was only slightly higher and
thus comparable with that found in Italian adolescents
with T1DM [28]. Interestingly, in these young patients,
women had a higher rate of abdominal adiposity, and male
adolescents had higher mean systolic blood pressure values,
which were not observed in our cohort. In accordance with
our results, HbA1c was only slightly but insignificantly
Table 3 Evaluation of risk for retinopathy, nephropathy and/or peripheral neuropathy by multivariate analyses
Parameter Univariate analysis Multivariate discriminant function analysis Multivariate regression analysis
(P-values) (P-values) (P-values)
Retinopathy Nephropathy Neuropathy Retinopathy Nephropathy Neuropathy Microvascular diseases
m f m f m f m f m f m f m f
Duration T1DM 0.021 0.043 0.253 0.553 0.079 0.098 0.000 0.000 0.330 0.534 0.049 0.041 0.000 0.001
BMI 0.036 0.312 0.028 0.299 0.249 1.000 0.025 0.635 0.109 0.005 0.298 0.467 0.011 0.039
Total cholesterol 0.352 0.246 0.439 0.017 0.750 0.041 0.021 0.019 0.017 0.426 0.958 0.522 0.002 0.666
LDL cholesterol 0.252 0.031 0.393 0.052 0.264 0.500 0.184 0.022 0.074 0.015 0.465 0.537 0.023 0.084
HDL cholesterol 0.405 0.032 0.052 0.383 0.247 0.659 0.106 0.018 0.038 0.589 0.695 0.511 0.002 0.640
Triglycerides 0.049 0.049 0.421 0.040 0.149 0.169 0.009 0.029 0.178 0.273 0.263 0.578 0.007 0.732
Syst./Diast. RR 0.005 0.006 0.000 0.002 0.806 0.637 0.940 0.141 0.223 0.797 0.657 0.867 0.621 0.483
HbA1c 0.536 0.005 0.150 0.998 0.212 1.000 0.315 0.082 0.780 0.265 0.238 0.315 0.381 0.453
Men (m), Women (f), Systolic/Diastolic blood pressure (Syst./Diast. RR).
Table 4 Gender-dependent adherence to general cardio-preventive criteria
Criteria Adherence (%) [95% Cl]
Men Women
n=123 n=102
High level of adherence to general cardio-preventive measures
• Patient with apparent contraindication/intolerance to aspirin therapy is prescribed clopidogrel 75 mg 100 100
• Prescribing of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin II receptor
blockers (ARBs) post myocardial infarction
100 100
• Prescribing of beta-blocker in post myocardial infarction patients or in patients with coronary heart disease 68.8 [56.7-80.9] 88.0* [76.1-97.9]
• Prescribing of ACE-I/ARB in patients with microalbuminuria/proteinuria 76.1 [63.8-88.4] 75.7 [61.9-89.5]
Intermediate level of adherence to general cardio-preventive measures
• Patient aged ≥40 years is prescribed a statin when pretreatment serum cholesterol was ≥200 mg/dl 67.4 [57.7-77.2] 60.9 [50.7-71.2]
Low level of adherence to general cardio-preventive measures
• Patient who is described a statin has achieved a triglyceride level of 350 mg/dl and LDL level of 80 mg/dl 40.3 [28.1-52.5] 19.6** [4.0-24.8]
• Patient aged ≥50 years is prescribed aspirin 53.4 [42.0-64.9] 37.1* [25.8-48.5]
• Patients aged <50 years with cardiovascular risk factors is prescribed aspirin 5.9 [0–17.1] 0
• Patient who continues to smoke has been offered smoking cessation advice which involves structured
behavioural support plus nicotine replacement therapy or bupropion/varenicline
0 0
* P < 0.05, ** P < 0.01.
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higher in the female patients. In another study, insulin
resistance and increased carotid intima-media thickness
characterised adolescent T1DM patients without the char-
acteristics of MetS, suggesting that insulin resistance and
early atherosclerosis may already be present in lean T1DM
patients [29]. Similarly, in a longitudinal study in children
and adolescents with T1DM, the carotid intima-media
thickness was elevated compared with the healthy controls,
and these patients further progressed in subclinical
atherosclerosis during a four year period [30]. Blood
pressure and BMI were related to its increment, with
no gender differences in the carotid intima-media thickness
values. In the SEARCH CVD study age, sex, adiposity
and systolic blood pressure were determinants of increased
IMT in youth with T1DM, but after adjustment of HbA1c
these differences disappeared emphasizing the importance
of good glycaemic control [31].
Several studies confirmed worse glycaemic control in
female diabetic subjects, but most studies referred to elderly
patients with T2DM. Data from a German database showed
that female gender, age, duration of diabetes and minority
status was significantly associated with poor glycaemic con-
trol in T1DM [7]. Similarly, a cross-sectional analysis of the
Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications (DCCT/EDIC)
cohort reported that women were less likely than men
to achieve HbA1c<7.0%, whereas the achievement of
target lipid levels was not significantly different between the
sexes [32]. In contrast, the gender-specific characterisation
of children and adolescents with T1DM in Austria and
Germany showed differences in the distribution of car-
diovascular risk factors in disfavour of females, including
higher cholesterol levels [33]. In our study, women showed
higher mean total cholesterol levels than men, and overall,
women tended to feature hyperlipidaemia more often than
their male counterparts. In the obese and hypertonic sub-
groups, LDL cholesterol was also higher in the women than
in the men. In contrast, triglycerides were higher in men
than in women but only in the obese group, and in those
patients with insufficient glycaemic control, this difference
became significant. Similar findings were observed in an-
other, smaller longitudinal study in patients with T1DM at
Table 5 Gender-dependent adherence to hypertension criteria
Criteria Adherence (%) [95% Cl]
Men Women
n=123 n=102
High level of adherence to hypertension criteria
• Prescribing of antihypertensive drug(s) in hypertensive diabetic patient 100 100
• No co-prescribing of thiazide + beta blocker in treated hypertension 100 100
• Patient diagnosed with hypertension has a treatment plan that does NOT include oral contraceptives,
corticosteroids, NSAIDs, high sodium containing products, sympathomimetics, monoamine oxidase inhibitors
96.9 [92.6-100] 84.6* [74.8-94.5]
• Addition of a calcium channel blocker (CCB) and/or diuretic in patients whose blood pressure
remains uncontrolled with ACE-Is or ARBs
89.7 [80.2-99.3] 87.8 [78.6-96.9]
• Prescribing of an ACE-I or ARB in hypertensive patient 85.9 [74–94.5] 87.1 [78.8-95.4]
Low level of adherence to hypertension criteria
• Achievement of blood pressure target in patients on aspirin 34.1 [20.1-48.1] 23.1 [6.9-39.3]
• Patient with treated hypertension and with co-existing kidney, eye or cerebrovascular damage and/or
with two or more features of MetS has achieved blood pressure control of ≤130/80 mmHg
16.4 [7.1-25.7] 10.2 [2.5-17.9]
* P < 0.05.
Table 6 Gender-dependent adherence to diabetes management
Criteria Adherence (%) [95% Cl]
Men Women
n=123 n=102
High level of adherence to diabetes management
• Prescribing of insulin 100 100
• Test blood glucose themselves 100 100
• Patients with a diagnosis of DM of at least 15 months has had two
HbA1c measurements taken at least twice within the past 15 months
92.9 [87.9-98] 91.4 [85.7-97.1]
Intermediate/Low level of adherence to diabetes management
• Achievement of HbA1c<6.5% in patients on insulin 56.7 [45.2-68.2] 43.4* [32.8-54.0]
* P < 0.05.
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our institution [34] and in many studies on T2DM patients
[9]. Moreover, data from the EURODIAB PCS recently
clearly showed that women with T1DM had higher total-
cholesterol concentrations than their male counterparts [5].
The cross-section Brazilian Type 1 Diabetes Study
reported complex and heterogeneous relationships between
glycaemic control and fasting lipids but low HDL choles-
terol consistently related to exogenous hyperinsulinaemia
[35]. However, the analyses were not performed separately
by gender.
US adults with diabetes were shown to be at lower
short-term CVD risk than previously assumed with pro-
portionately fewer high-risk persons among the females
and those with T1DM by using global risk assessment
equations for total CVD [36]. However, almost 30% had
pre-existing CVD without sex differences. It should be
mentioned that most risk scores were derived from
predominantly male cohorts and that the risk may be
underestimated in female diabetic patients. In addition,
this study reported that less than 15% of all diabetic
patients simultaneously achieved their HbA1c, blood
pressure and cholesterol goals. With respect to diabetic
complications, no sex differences were found in the rates
of micro- or macrovascular complications in general
(Figure 1A-C; Table 2); in both sexes, retinopathy was
most prevalent followed by nephropathy, whereas car-
diovascular diseases tended to be higher in women than
in men without reaching statistical significance as only a
few events were documented in this small cohort in both
sexes. These events occurred only after a disease duration
of more than 10 years. However, the absence of a gender
difference in CVD with even more events in women clearly
supports the notion that diabetes reverses the sex-related
risk relationship in the non-diabetic population and that
diabetes is particularly harmful in women. Although the
reason for these sex-dimorphic effects in diabetes is not
entirely clear at present, there are several hypothesis
underlining the importance of sex-specific risk factors. In
adolescents with T1DM but not in healthy subjects, girls
had a higher per-cent of trunk fat compared with boys,
whereas other cardiovascular risk factors, including vas-
cular elasticity, did not differ in children with or without
diabetes [37]. Thus, more centrally distributed fat could
also contribute to the relatively higher cardiovascular
risk in females with T1DM. Of note, higher trunk fat
mass was associated with a higher prevalence of coronary
heart disease only in female T1DM in the Pittsburgh
Epidemiology of Diabetes Complications cohort [38].
However, a higher stiffness of the central elastic arteries
was also found in older female T1DM patients compared
with their male counterparts [39]. The Coronary artery
calcification in type 1 diabetes study showed that T1DM
increases the prevalence and severity but reduces the
gender differences of coronary artery calcification [40].
Gender differences in insulin resistance-associated fat
deposition and in HDL and LDL cholesterol distribution
may explain why type 1 diabetes increases coronary calcifi-
cation in women relatively more than in men. Furthermore,
female sex hormones, particularly oestrogen, may exert
beneficial effects on the cardiovascular system and energy
metabolism, which could be impaired in diabetic women
potentially via an unfavourable oestrogen receptor balance
and distribution [41]. In fact, diabetes status has been
shown to abolish the vascular protective effect of oestrogen
in female rats [42]. This lack of the protective effects of
oestrogen was mainly ascribed to its failure to reverse
the impaired basal release of NO and the abnormal
relaxation to histamine in the aorta of diabetic female
rats. Furthermore, this risk could be related to dietary
fat intake and lifestyle [10]. Altogether in humans, the
relationship among sex hormones, gender, diabetes and
vascular disease is complex and not fully understood.
Given that this “diabetes gender paradox” also refers to
T1DM, the importance of hyperglycaemia in addition to
other cardiovascular risk factors that usually accompany
T2DM is further suggested.
Regarding microvascular complications, among the
hyperlipidaemic subgroups, women had a much higher rate
of neuropathy than those with normal lipids. Nephropathy
was highest in obese males, in hyperlipidaemic females and
in hypertensive patients of both sexes. Many other studies
found the male sex to be a risk factor for nephropathy,
which accompanies a potential protective effect of oestrogen
that was shown in experimental models of retinopathy and
nephropathy [43,44]. An increased risk of retinopathy was
observed in both sexes with a disease duration longer than
10 years, obesity and hypertension, whereas insufficient gly-
caemic control was associated with a higher rate in women
but not in men. Diabetic retinopathy is the major diabetic
microvascular complication in T1DM [45] and may also
increase the risk for all-cause mortality and incidence of
CVD [46]. The presence of cardiovascular risk factors
explained the associations to a large extent, except for the
association with proliferative retinopathy, which suggests
that other shared mechanisms may be involved. In the
Prospective German Diabetes Documentation System
Survey, diabetic retinopathy in T1DM patients [47] was
associated with the male sex in addition to established
risk factors. However, regarding sex as a risk factor, the
results are controversial. Similar to the study by Monti,
a recently published cross-sectional population-based study
from Finland reported that female sex together with a
longer duration of disease, older age and higher HbA1c
explained 35% of diabetic retinopathy [48]. Of note, females
appeared to have better control but a higher risk of retinop-
athy. However, there are also reports on a higher risk in
male patients [49]. Furthermore, higher testosterone levels
were found in patients with proliferative retinopathy [50].
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Therefore, the impact of sex on the onset and progression
of retinopathy is unclear at present, and in accordance with
the data of our small cohort, additional risk factors can be
hypothesised to contribute to an increased risk in one or
the other sex. Therefore, basic mechanistic studies and
longitudinal clinical data in large cohorts are necessary
to clarify the impact of sex and gender-related risk factors
on the development of diabetic complications.
Intensive diabetes therapy during the DCCT was
shown to decrease carotid artery intima-media thickness
(IMT) progression and thus atherosclerosis during 12 years
of EDIC follow-up compared with conventional therapy
[51]. However, only in men was the IMT significantly
lower in the intensified therapy compared with the standard
therapy after 6 years of follow-up despite similar differences
in glycaemic control between both sexes. The beneficial
effects of intensified therapy and better HbA1c on IMT
during EDIC were partially mediated by the effects on
blood pressure and hypertension. In a previous study
in patients with T2DM, women had a similar rate of
myocardial infarctions and cerebral ischaemia compared
with men but a lower rate of coronary interventions
and less aspirin therapy [9]. Many studies proved sex
differences in the use of antihypertensive, lipid-lowering
or antifibrinolytic drug therapies in patients with T2DM
[3,52,53], but there are only a few studies in T1DM. In the
present study, the overall adherence to pharmacological
intervention according to specific guidelines was lower in
females than in males in the T1DM subjects. Low adher-
ence was found for the prescription of statins, achievement
of treatment goals for lipids, and for the prescription of
aspirin in patients with prominent cardiovascular risk
younger than 50 years. Again, the adherence was even
lower in women than in men. However, no difference
was found in the antihypertensive or antihyperglycaemic
treatments (insulin regimes) and in the cardioprotective
measurements between both sexes. In the DCCT/EDIC
cohort, women were also significantly less likely than men
to report using aspirin and statins as well as angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers [32], showing that risk-reducing therapies are
underused in women with diabetes. Of note in our small
cohort of patients with CHD, female patients even had
higher prescription rates of beta-blockers than male
patients. Therefore, efforts to increase awareness about the
cardiovascular risk in diabetic females seems to show some
benefits; improving the guideline-based clinical practice
and adherence to drug therapy must be a major target in all
diabetic patients, independent of sex.
Our study has several limitations. This is a cross-
sectional analysis, and therefore no data on the pro-
gression of complications or survival are available. The
adherence to prescription according to guidelines is
objectively documented, but the adherence/compliance
of the patient to his/her medications is self-reported
and might be overestimated. The sample is relatively small,
and thus additional studies in larger cohorts including
longitudinal data are recommended to further study
the important sex differences in T1DM.
Conclusions
In summary, our results support the hypothesis that the
female sex may lose its general cardiovascular advantage
in diabetic subjects as women had comparable rates of
micro- and macrovascular complications with even more
cardiovascular events. Obesity and dyslipidaemia may exert
sex-dimorphic effects on the development of long-term
complications, whereas hypertension and a long duration of
disease are related to complications in both sexes. Women
were less likely to be treated with statins and aspirin and
had a worse metabolic situation with higher total cholesterol
levels than males with T1DM. Adherence to pharmaco-
logical intervention according to the guidelines was lower in
women than in men. Therefore, differences in the treatment
may contribute to this gender-difference in cardiometabolic
risk. A continuing need for improvements in the treatment
and care is essential in all patients with T1DM but is
particularly striking for female type 1 diabetics.
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